CRL · Charles River Laboratories International
352 filings
CRL SEC Filings
Charles River Laboratories International - 352 total filings
CRL filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 118 current reports (8-K) between 2016 and 2026.
- 8-K · Jan 8, 2016
- 8-K · Jan 19, 2016
- 8-K · Feb 10, 2016
- 10-K · Feb 12, 2016
- 8-K · Mar 10, 2016
- 8-K · Apr 5, 2016
- 8-K · May 4, 2016
- 10-Q · May 4, 2016
- 8-K · May 16, 2016
- 8-K/A · May 16, 2016
- 8-K/A · Jun 15, 2016
- 10-Q · Aug 3, 2016
- 8-K · Aug 3, 2016
- 8-K · Nov 2, 2016
- 10-Q · Nov 2, 2016
- 8-K · Nov 2, 2016
- 8-K · Jan 10, 2017
- 10-K · Feb 14, 2017
- 8-K · Feb 14, 2017
- 8-K · Apr 26, 2017
- 8-K · May 10, 2017
- 10-Q · May 10, 2017
- 8-K · May 11, 2017
- 8-K · Jul 6, 2017
- 10-Q · Aug 9, 2017
- 8-K · Aug 9, 2017
- 8-K · Nov 9, 2017
- 10-Q · Nov 9, 2017
- 8-K · Nov 24, 2017
- 8-K · Jan 9, 2018
- 8-K · Jan 16, 2018
- 8-K · Feb 13, 2018
- 10-K · Feb 13, 2018
- 8-K · Feb 13, 2018
- 8-K · Feb 13, 2018
- 8-K · Mar 26, 2018
- 8-K · Apr 3, 2018
- 8-K · May 10, 2018
- 10-Q · May 10, 2018
- 8-K · May 14, 2018
- 8-K · Jun 14, 2018
- 8-K/A · Jun 14, 2018
- 10-Q · Aug 8, 2018
- 8-K · Aug 8, 2018
- 8-K · Aug 8, 2018
- 8-K · Aug 31, 2018
- 8-K · Oct 3, 2018
- 10-Q · Nov 7, 2018
- 8-K · Nov 7, 2018
- 10-K · Feb 13, 2019
- 8-K · Feb 13, 2019
- 8-K · Feb 15, 2019
- 8-K · Apr 30, 2019
- 8-K · May 1, 2019
- 10-Q · May 7, 2019
- 8-K · May 7, 2019
- 8-K · May 22, 2019
- 8-K · Jul 31, 2019
- 10-Q · Jul 31, 2019
- 8-K · Aug 2, 2019
- 8-K · Oct 1, 2019
- 8-K · Oct 21, 2019
- 8-K · Oct 23, 2019
- 10-Q · Nov 6, 2019
- 8-K · Nov 6, 2019
- 8-K · Feb 11, 2020
- 10-K · Feb 11, 2020
- 8-K · Mar 4, 2020
- 10-Q · May 7, 2020
- 8-K · May 7, 2020
- 8-K · May 8, 2020
- 8-K · Aug 5, 2020
- 10-Q · Aug 5, 2020
- 8-K · Oct 19, 2020
- 8-K · Oct 29, 2020
- 10-Q · Oct 29, 2020
- 10-K · Feb 17, 2021
- 8-K · Feb 17, 2021
- 8-K · Feb 17, 2021
- 8-K · Mar 9, 2021
- 8-K · Mar 23, 2021
- 8-K · Mar 29, 2021
- 8-K · Apr 23, 2021
- 10-Q · May 4, 2021
- 8-K · May 4, 2021
- 8-K · May 10, 2021
- 8-K · May 18, 2021
- 10-Q · Aug 4, 2021
- 8-K · Aug 4, 2021
- 10-Q · Nov 3, 2021
- 8-K · Nov 3, 2021
- 8-K · Nov 9, 2021
- 8-K · Nov 12, 2021
- 8-K · Dec 15, 2021
- 8-K · Dec 27, 2021
- 8-K · Jan 11, 2022
- 10-K · Feb 16, 2022
- 8-K · Feb 16, 2022
- 8-K · Mar 28, 2022
- 10-Q · May 4, 2022
- 8-K · May 4, 2022
- 8-K · May 12, 2022
- 8-K · Jun 8, 2022
- 8-K · Aug 3, 2022
- 10-Q · Aug 3, 2022
- 10-Q · Nov 2, 2022
- 8-K · Nov 2, 2022
- 8-K · Nov 30, 2022
- 8-K · Dec 6, 2022
- 10-K · Feb 22, 2023
- 8-K · Feb 22, 2023
- 8-K · May 11, 2023
- 10-Q · May 11, 2023
- 8-K · May 15, 2023
- 10-Q · Aug 9, 2023
- 8-K · Aug 9, 2023
- 10-Q · Nov 8, 2023
- 8-K · Nov 8, 2023
- 8-K · Nov 15, 2023
- 8-K · Jan 16, 2024
- 8-K · Jan 24, 2024
- 10-K · Feb 14, 2024
- 8-K · Feb 14, 2024
- 10-Q · May 9, 2024
- 8-K · May 9, 2024
- 8-K · May 10, 2024
- 8-K · Aug 7, 2024
- 10-Q · Aug 7, 2024
- 8-K · Nov 6, 2024
- 10-Q · Nov 6, 2024
- 8-K · Dec 13, 2024
- 8-K · Jan 14, 2025
- 10-K · Feb 19, 2025
- 8-K · Feb 19, 2025
- 8-K · Feb 21, 2025
- 8-K · May 7, 2025
- 10-Q · May 7, 2025
- 8-K · May 7, 2025
- 8-K · May 23, 2025
- 10-Q · Aug 6, 2025
- 8-K · Aug 6, 2025
- 8-K · Sep 16, 2025
- 8-K/A · Sep 19, 2025
- 8-K · Nov 5, 2025
- 10-Q · Nov 5, 2025
- 8-K · Nov 17, 2025
- 8-K · Dec 3, 2025
- 8-K · Jan 9, 2026
- 8-K · Jan 13, 2026
- 10-K · Feb 18, 2026
- 8-K · Feb 18, 2026
- 8-K · Feb 18, 2026
- 8-K · Feb 25, 2026
- 10-Q · May 7, 2026
- 8-K · May 7, 2026
- 8-K · May 11, 2026
- 10-Q · Aug 5, 2026
- 8-K · Aug 5, 2026
- 8-K · Sep 24, 2026
- 10-Q · Nov 4, 2026
- 8-K · Nov 4, 2026
- 8-K · Nov 9, 2026
Charles River Laboratories International 8-K Report, Regulation FD Disclosure (Nov 9, 2026)
Charles River Laboratories International (CRL) has announced a definitive agreement to acquire Frontage Holdings Corporation's bioanalysis and DMPK operations in Exton, Pennsylvania, for approximately $470 million in cash, plus potential performance-based payments up to $75 million. This strategic acquisition is expected to close in the first half of 2027, subject to customary approvals. The transaction is designed to significantly strengthen CRL's bioanalysis capabilities, particularly in the high-growth clinical bioanalysis sector, and enhance its offering across the entire drug development lifecycle. This move aligns with CRL's "Pathway to Purpose" strategy, aiming to bolster scientific leadership, expand its presence in complex modalities, and improve client continuity from preclinical to clinical testing. The acquired operations include two sites in Exton, PA, approximately 150,000 square feet, and employ around 340 people. Frontage's bioanalysis and DMPK businesses represented about 40% of their total 2025 revenue. CRL anticipates the acquired businesses will grow in line with the projected bioanalysis sector growth. While expected to be neutral to non-GAAP EPS in 2027, the acquisition is projected to be accretive thereafter, with financing to be drawn from the company's credit facility and available cash.
Charles River Laboratories International Quarterly Report for Q3 Ended Sep 26, 2026
Charles River Laboratories International, Inc. reported third-quarter 2026 total revenue of $982.7 million, a decrease of $22.1 million, or 2.2%, from $1,004.9 million a year earlier. Nine-month revenue was $2,982.6 million versus $3,021.2 million, down 1.3%. The decline reflects the sale of the CDMO and Cell Solutions businesses and the European Discovery Services businesses, partly offset by growth in Microbial Solutions, Biologics Testing and regulated safety assessment. Operating income rose to $202.6 million (20.6% of revenue) for the quarter from $133.8 million (13.3%), and net income attributable to common shareholders increased to $333.1 million from $54.4 million, driven mainly by a $201 million tax benefit from the reversal of an unrecognized tax benefit reserve. Diluted EPS for the quarter was $6.86 versus $1.10. The nine-month results included a $181.7 million pre-tax loss on the CDMO and Cell Solutions divestiture, which the company recorded within Other expense, net. Cash flow from operations was $474.9 million, down from $590.1 million, mainly due to higher variable compensation payments. The company spent $467.3 million on acquisitions, including the Cambodian NHP Supplier and PathoQuest, and repurchased $300.0 million of stock, leaving $700.0 million available under its program. Total debt and finance leases rose to $2.46 billion, with the revolving facility balance at $943.2 million. Management announced the multi-year Create the Future restructuring program in September 2026, targeting more than $300 million of incremental annualized cost savings between 2027 and 2030. The filing also discloses an ongoing putative securities class action and two stayed derivative lawsuits, all tied to importation of non-human primates. The company states it believes these claims are without merit and cannot reasonably estimate potential exposure or loss.
Charles River Laboratories International 8-K Report, Financial Results (Nov 4, 2026)
Charles River Laboratories International, Inc. (NYSE: CRL) reported third-quarter 2026 results for the quarter ended September 26, 2026, in a press release furnished as Exhibit 99.1 to this Form 8-K. Third-quarter revenue was $982.7 million, down from $1,004.9 million a year earlier, mainly due to the May 2026 divestitures; on an organic basis revenue rose 4.7%. GAAP earnings per diluted share were $6.86, boosted by a $245.6 million, or $5.06 per share, benefit from the reversal of acquired tax reserves. Non-GAAP diluted EPS was $3.09, up 27.2% from $2.43. The company raised its 2026 guidance. Organic revenue growth is now expected to be at least +1.5% (previously 0.0% to 1.0%), and non-GAAP EPS is now $11.35 to $11.55 (previously $11.15 to $11.45). GAAP EPS guidance rose to $8.15 to $8.35 from $3.05 to $3.35. Management attributed the increase mainly to better-than-expected DSA segment performance and a lower tax rate. Management also highlighted the 2026 Investor Day unveiling of its Pathway to Purpose strategy and Create the Future initiative. Segment results were mixed. DSA revenue was $596.3 million, with organic growth of 5.9% and non-GAAP operating margin of 26.8%. Manufacturing Solutions revenue was $178.9 million, with organic growth of 7.4% and non-GAAP operating margin of 38.6%. Research Models and Services revenue was $207.5 million, with organic revenue down 0.6% and non-GAAP operating margin of 24.4%.
Charles River Laboratories International 8-K Report, Regulation FD Disclosure (Sep 24, 2026)
Charles River Laboratories International, Inc. (NYSE: CRL) furnished a press release dated September 24, 2026, issued in connection with its 2026 Investor Day. The release outlines the company's "Pathway to Purpose" strategy, which rests on three initiatives: modernizing the company to drive productivity and efficiency, strengthening its scientific portfolio, and delivering a customized, client-centric approach. The company expects over $300 million in cumulative savings from its Create the Future™ program from 2027 through 2030, and it expects bioanalysis revenue to grow organically at a high-single-digit CAGR to approximately $450 million in 2030. The company reaffirmed its 2026 financial guidance, last updated on August 5, 2026, and now expects revenue and non-GAAP earnings per share at the upper ends of their prior ranges, primarily reflecting continued favorable demand from biopharmaceutical clients. The 2026 guidance ranges are 0% to 1% organic revenue growth, a non-GAAP operating margin of 21.0% to 21.3%, and non-GAAP EPS of $11.15 to $11.45. For 2030, the company introduced long-term targets of 5% to 7% organic revenue growth (2027-2030 CAGR), a non-GAAP operating margin of approximately 24%, and low-double-digit non-GAAP EPS growth (2027-2030 CAGR). The company states these targets do not include future acquisitions or divestitures, are not projections, and are not financial guidance. The information is furnished under Item 7.01 and is not deemed filed for purposes of Section 18 of the Exchange Act.
Charles River Laboratories International 8-K Report, Financial Results (Aug 5, 2026)
Charles River Laboratories International, Inc. reported second-quarter 2026 results for the quarter ended June 27, 2026, with revenue of $1.00 billion, down 2.7% from $1.03 billion a year earlier, and organic revenue growth of 0.1%. GAAP results were weaker, with a net loss attributable to common shareholders of $(1.5) million, or $(0.03) per diluted share, compared with net income of $52.3 million, or $1.06 per share, a year earlier. The company attributed the decline mainly to a $63.7 million, or $1.40 per share, loss on the CDMO and Cell Solutions divestiture. On a non-GAAP basis, diluted EPS was $3.02, versus $3.12 in the prior-year quarter, and the non-GAAP operating margin fell to 20.5% from 22.1%, mainly on higher study-related direct costs in the DSA segment. Management cited improving demand, particularly in the DSA segment, where it recorded the highest net book-to-bill in nearly four years. Based on second-quarter performance and improving demand trends, the company raised its 2026 guidance: organic revenue growth is now 0.0% to 1.0% (previously (1.5)% to (0.5)%), and non-GAAP EPS is now $11.15 to $11.45 (previously $10.80 to $11.30). GAAP EPS guidance was lowered to $3.05 to $3.35 from $5.35 to $5.85, primarily because of the divestiture-related net loss. The company also repurchased $100.0 million of stock in the quarter and has $700.0 million remaining under its $1.0 billion authorization. An Investor Day is scheduled for September 24, 2026.
Charles River Laboratories International Quarterly Report for Q2 Ended Jun 27, 2026
Charles River Laboratories International, Inc. reported second-quarter 2026 total revenue of $1,004.1 million, down $28.1 million, or 2.7%, from $1,032.1 million a year earlier. Revenue for the six months ended June 27, 2026 was $1,999.9 million, down 0.8% from $2,016.3 million. The decline reflected the sale of the CDMO business and the European Discovery Services divestiture, along with lower cell supply revenue. Operating income rose to $119.9 million, or 11.9% of revenue, from $100.1 million, or 9.7%, mainly because of a gain on the Wilmington, Massachusetts asset sale, lower accelerated amortization, and lower 2025 third-party legal costs. Net loss attributable to common shareholders was $1.5 million for the quarter, compared with net income of $52.3 million in the prior-year quarter. The result was driven by a $63.7 million loss on the CDMO and Cell Solutions divestiture. For the six months, the company reported a net loss attributable to common shareholders of $16.3 million, including a $181.7 million divestiture loss. Cash flow from operations was $220.8 million for the six months, compared with $376.3 million a year earlier. The company attributed the decline to higher variable compensation payments and acquisition, integration and divestiture-related payments. Investing activities included $467.3 million for acquisitions, primarily the Cambodian NHP supplier with a preliminary purchase price of $507.3 million, and PathoQuest, at $67.6 million. Total long-term debt, net and finance leases rose to $2.62 billion from $2.14 billion, with the revolving facility balance increasing to $1.12 billion from $616.5 million. The company repurchased $300.0 million of stock during the six months and had $700.0 million remaining under its repurchase authorization at June 27, 2026. Management stated that cumulative annualized cost savings of approximately $300 million are expected by the end of 2026, and that DSA backlog increased slightly to $2.0 billion from $1.9 billion. The filing also discloses a putative securities class action and two derivative lawsuits, which management believes are without merit. The company cannot reasonably estimate the potential exposure from these matters.
Charles River Laboratories International 8-K Report, Executive Changes (May 11, 2026)
Charles River Laboratories International, Inc. filed this Form 8-K dated May 11, 2026 to report the results of its 2026 annual meeting of shareholders, held May 5, 2026. At the meeting, shareholders approved the company's 2026 Long-Term Incentive Plan, which the Board had adopted on March 11, 2026, subject to shareholder approval. The filing states that the full description of the plan appears in the Proxy Statement filed March 31, 2026, and that the plan itself is attached as Exhibit 10.1. All twelve director nominees were elected to serve until the 2027 annual meeting. Shareholders also approved, on an advisory basis, the compensation of the named executive officers, approved the 2026 Long-Term Incentive Plan, and ratified PricewaterhouseCoopers LLP as independent auditors for fiscal 2026. The vote on the auditor ratification was the one proposal where the filing reports zero broker non-votes, and the filing identifies Computershare Trust Company, N.A. as the independent proxy tabulator and inspector of election. For investors, the filing's key takeaways are the shareholder approval of the new incentive plan and the continued election of the full board slate. Vote counts for Abraham Ceesay (35,798,426 for and 8,288,770 against) were noticeably lower in support than those of the other directors, and the filing reports them without further commentary.
Charles River Laboratories International Quarterly Report for Q1 Ended Mar 28, 2026
Charles River Laboratories International, Inc. reported a first-quarter 2026 net loss attributable to common shareholders of $14.8 million ($0.30 per diluted share), compared with net income of $25.5 million ($0.50 per diluted share) in the prior-year quarter. The decline was driven principally by a $118.0 million pre-tax loss on assets held for sale tied to the CDMO and Cell Solutions Divestiture, which was completed on May 6, 2026. Total revenue rose $11.7 million, or 1.2%, to $995.8 million, led by Manufacturing (up 6.8%) and DSA (up 0.7%), partly offset by RMS (down 2.2%). Operating income increased 60.6% to $119.9 million, helped by a $38.5 million pre-tax gain on the sale of Wilmington, Massachusetts assets and the absence of prior-year accelerated amortization. Cash flow and balance sheet activity were significant. Operating cash flow fell to $41.1 million from $171.7 million, mainly due to higher annual incentive bonus payments. The company spent $405.0 million on acquisitions, primarily the Cambodian NHP Supplier, which closed January 14, 2026 for a preliminary purchase price of $507.3 million. Long-term debt, net rose to $2.66 billion from $2.14 billion, with the revolving facility balance increasing to $1.17 billion. The company repurchased $200.0 million of stock during the quarter and had $800.0 million remaining under its $1.0 billion authorization. Management stated that DSA backlog was consistent at $1.9 billion and that the client base remains cautious in spending, principally in DSA. The company also disclosed a cybersecurity incident involving unauthorized access to certain information systems, which it said had not had a material impact as of the filing date, and noted ongoing securities and derivative litigation related to non-human primate importation disclosures.
Charles River Laboratories International 8-K Report, Financial Results (May 7, 2026)
Charles River Laboratories International, Inc. (NYSE: CRL) reported first-quarter 2026 results on May 7, 2026. Total revenue was $995.8 million, up 1.2% from $984.2 million a year earlier, though organic revenue declined 1.5% after adjusting for a 2.8% foreign currency benefit and a 0.1% divestiture reduction. GAAP results were weak: the company posted a net loss attributable to common shareholders of $(14.8) million, or $(0.30) per diluted share, versus net income of $25.5 million, or $0.50 per share, a year earlier. The decline was principally due to a $118.0 million loss on assets held for sale tied to the CDMO and Cell Solutions divestiture, or $1.53 per share. Non-GAAP diluted EPS was $2.06, down 12.0% from $2.34, and non-GAAP operating margin fell to 16.3% from 19.1%. By segment, Research Models and Services (RMS) revenue declined 2.2% reported and 5.5% organically, and Discovery and Safety Assessment (DSA) revenue rose 0.7% reported but fell 1.4% organically. Manufacturing Solutions grew 6.8% reported and 2.9% organically, supported by Microbial Solutions. The company completed the divestiture of its CDMO and Cell Solutions businesses to GI Partners on May 6, 2026, and expects to sell certain European Discovery Services sites in May 2026. It repurchased 1.1 million shares for $200.0 million in the quarter and had $800.0 million remaining under its $1.0 billion authorization. CRL reaffirmed its 2026 organic revenue growth guidance of (1.5)% to (0.5)% and non-GAAP EPS guidance of $10.80 to $11.30. It lowered its reported revenue growth outlook to (5.5)% to (4.0)% from (5.0)% to (3.5)%, reflecting foreign exchange assumptions, and set GAAP EPS guidance at $5.35 to $5.85.
Charles River Laboratories International 8-K Report, Regulation FD Disclosure (Feb 25, 2026)
On February 25, 2026, Charles River Laboratories International, Inc. announced two planned divestitures. It signed a definitive agreement to sell its contract development and manufacturing (CDMO) and Cell Solutions businesses to GI Partners, primarily for future, contingent performance-based payments. The businesses generated combined 2025 annual revenue of $143 million, including $117 million in the Manufacturing Solutions segment and $26 million in the Research Models and Services segment. The sale covers CDMO sites in Tennessee, Maryland, and the United Kingdom and a Cell Solutions site in California. Separately, the company signed a definitive agreement to sell certain European Discovery Services assets to IQVIA Holdings Inc. for approximately $145 million in cash, subject to customary closing adjustments, plus potential additional payments of up to $10 million. The assets represent $144 million of 2025 annual revenue in the Discovery and Safety Assessment segment. The company will retain other drug discovery capabilities totaling approximately 40% of its 2025 Discovery Services revenue. Both transactions are expected to close in the second quarter of 2026, subject to customary closing conditions. The company updated its 2026 guidance, first provided on February 18, 2026, to reflect the divestitures. The divestitures are expected to reduce reported revenue by slightly more than $200 million in 2026 and reduce organic revenue growth guidance by more than 50 basis points. Reported revenue growth/(decrease) is now guided to (5.0)% to (3.5)%, and organic revenue growth/(decrease) to (1.5)% to (0.5)%. Non-GAAP earnings per share guidance rises to $10.80 to $11.30 from $10.70 to $11.20, reflecting approximately $0.10 of partial-year accretion. The transactions are expected to add at least 100 basis points of non-GAAP operating margin improvement in 2026.
Charles River Laboratories International 8-K Report, Executive Changes (Feb 18, 2026)
Charles River Laboratories International, Inc. announced on February 18, 2026 that it has appointed Glenn Coleman as Corporate Executive Vice President and Chief Financial Officer, with a tentative start date of April 6, 2026. Mr. Coleman, 58, most recently served since 2024 as Chief Financial Officer and Chief Administrative Officer of Premier, Inc., described in the filing as a $1-billion healthcare services business. His earlier roles include CFO of DENTSPLY SIRONA Inc. and Integra Life Sciences Holdings Corporation, where he also served as Executive Vice President and Chief Operating Officer from 2019 to 2022. He succeeds Michael G. Knell, who has served as interim CFO since September 2025 and will remain Corporate Senior Vice President and Chief Accounting Officer. The filing describes an at-will employment offer letter dated February 12, 2026, with the following material terms: a base salary of $800,000 annually, a 2026 target bonus of 85% of base salary (pro-rated to his hire date), a 2026 equity award with a grant value of $3,000,000 (60% performance share units and 40% restricted stock units) beginning in May 2026, a one-time new hire cash award of $1,875,000, and a one-time new hire restricted stock unit award with a grant value of $3,500,000 vesting 25% annually over four years. The full offer letter is filed as Exhibit 10.1. The filing states there are no family relationships between Mr. Coleman and any director or executive officer, and no related-person transactions requiring disclosure under Item 404(a) of Regulation S-K.
Charles River Laboratories International 8-K Report, Financial Results (Feb 18, 2026)
Charles River Laboratories International, Inc. (NYSE: CRL) reported fourth-quarter and full-year 2025 results on February 18, 2026, under Item 2.02 of this Form 8-K. Fourth-quarter revenue was $994.2 million, a decrease of 0.8% from $1,002.5 million a year earlier; on an organic basis, revenue declined 2.6%. The GAAP net loss available to common shareholders was $(276.6) million, or $(5.62) per diluted share, driven by non-cash intangible asset impairments of $211.0 million and a goodwill impairment of $165.0 million in the Biologics Solutions reporting unit. Non-GAAP diluted earnings per share were $2.39, down 10.2% from $2.66. For full-year 2025, revenue was $4.02 billion, down 0.9%, with GAAP diluted loss per share of $(2.91) and non-GAAP diluted EPS of $10.28, down 0.4%. Segment performance was mixed. Fourth-quarter DSA net bookings improved substantially, which management cites as evidence of stabilizing biopharmaceutical demand, though DSA revenue fell 2.0% and its non-GAAP operating margin declined to 20.1% from 24.7%. RMS revenue rose 1.0%, while Manufacturing Solutions revenue rose 0.7% on a reported basis but fell 2.1% organically. For 2026, the company guides to reported revenue growth of at least flat to +1.5%, organic revenue growth of (1.0)% to at least flat, GAAP EPS of $6.30 to $6.80, and non-GAAP EPS of $10.70 to $11.20. The guidance excludes planned divestitures representing approximately 7% of annual revenue for 2025 and estimated 2026, and management expects a return to organic revenue growth in the second half of 2026.
Charles River Laboratories International Annual Report, Year Ended Dec 27, 2025
Charles River Laboratories International, Inc. (CRL) reported fiscal 2025 total revenue of $4.02 billion, down 0.9% from $4.05 billion in fiscal 2024, as lower DSA volumes outweighed higher RMS revenue. The company swung to a net loss available to common shareholders of $144.3 million (basic and diluted loss per share of $2.91), compared with net income of $10.3 million in 2024. The decline was driven by $210.97 million of intangible asset impairments, a $165.0 million goodwill impairment in Biologics Solutions, and a $102.0 million intangible impairment within RMS's Cell Solutions group. Operating income fell to $25.2 million (0.6% margin) from $227.3 million, and the effective tax rate was (42.9)%. Segment results show DSA revenue of $2.40 billion (59.8% of total) with operating income of $424.6 million, RMS revenue of $846.1 million with operating income of $44.6 million, and Manufacturing revenue of $766.4 million with an operating loss of $184.3 million. Management described early signs of demand improvement, particularly from large biopharma clients in DSA, and expects approximately $300 million in cumulative annualized cost savings by the end of 2026. Operating cash flow was $737.6 million, and total debt and finance leases were $2.1 billion at year-end. The company also disclosed that it acquired certain assets of K.F. (Cambodia) Ltd. in January 2026 for $510.0 million, plans to acquire the remaining 79% of PathoQuest SAS for approximately $60 million, and expects to divest non-core assets representing about 7% of 2025 revenue. Leadership is changing: James C. Foster will step down as CEO and Chair effective May 5, 2026, and Birgit Girshick has been appointed as his successor. The company faces ongoing litigation, including a putative securities class action that was partially reinstated on appeal in August 2025, and two stayed derivative lawsuits. Management says it cannot estimate the potential exposure from these matters. The SEC closed its investigation in November 2025 without recommending enforcement, and the DOJ closed its related grand jury and civil investigations in August 2025.
Charles River Laboratories International 8-K Report, Financial Results (Jan 13, 2026)
Charles River Laboratories International, Inc. ("Charles River") filed this Form 8-K on January 13, 2026 to furnish materials for its presentation at the J.P. Morgan 44th Annual Healthcare Conference. The company stated that demand trends for its Discovery and Safety Assessment (DSA) business continued to improve throughout the second half of 2025, with a preliminary DSA net book-to-bill of approximately 1.1x in the fourth quarter of 2025. Improvement was primarily driven by small and mid-sized biotech clients, and global biopharma net bookings also increased in the fourth quarter of 2025. The company noted that these preliminary figures remain subject to completion of its audited 2025 results. For 2026, Charles River expects the top end of its organic revenue growth guidance ranges to be at least flat for both the consolidated outlook and the DSA segment. The company is cautiously optimistic that favorable DSA demand indicators will continue into 2026, resulting in a return to revenue growth in the second half of 2026. Expected improvement in Manufacturing organic revenue growth is anticipated to be offset by RMS headwinds from the timing of non-human primate (NHP) shipments and CRADL occupancy. Foreign exchange is expected to be an incremental benefit of 100-150 bps to reported revenue growth. The company also expects more than $100 million in incremental 2026 cost savings to offset annual cost inflation until revenue growth reinvigorates. Charles River also disclosed two acquisitions. It has signed an agreement to acquire the assets of K.F. (Cambodia) Ltd., a provider of non-human primates, for an expected total purchase price of approximately $510 million, closing early in the first quarter of 2026 and expected to be accretive to non-GAAP EPS by approximately $0.25 in 2026 and $0.60 in 2027. It has also exercised its option to acquire the remaining 79% stake in PathoQuest SAS for approximately €51.6 million (about $60 million), expected to close by the end of the first quarter of 2026. PathoQuest is expected to generate annual revenue of approximately $15 to $20 million in 2026 and is not expected to have a material impact on 2026 or 2027 GAAP or non-GAAP results. The 2026 outlook does not yet reflect these acquisitions or planned divestitures.
Charles River Laboratories International 8-K Report, Executive Changes (Jan 9, 2026)
Charles River Laboratories International, Inc. announced a CEO leadership transition on January 8, 2026. James C. Foster, currently Chairman, President and Chief Executive Officer, intends to step down as CEO and Chairman of the Board, and Birgit Girshick, the Company's Chief Operating Officer, will become CEO, both effective May 5, 2026 (the "Transition Date"). Foster is expected to remain a non-executive director afterward, and Dr. Martin Mackay, the current Lead Independent Director, is expected to become Chair of the Board on the Transition Date. Girshick has also been nominated to join the Board at the 2026 Annual Meeting of Shareholders, expected on the Transition Date, and the Board approved increasing its size from 11 to 12 seats effective then. Elliott Investment Management L.P. and related Elliott entities provided limited consents under their May 6, 2025 Cooperation Agreement with the Company to permit this addition. Compensation terms for Girshick include a base salary increase to $1,200,000 effective February 1, 2026, a target annual cash incentive of 100% of base salary effective May 1, 2026, and an initial equity grant with a target fair market value of $9,000,000 (80% performance share units, 20% restricted stock units) expected in May 2026. Her change-in-control agreement is to be amended before the Transition Date, providing a lump sum severance of three times base salary plus target bonus, three years of benefits continuation, and outplacement services upon a qualifying termination within the first year after a change in control. Foster received a grant of restricted stock units with an underlying fair market value of $3,000,000, expected on March 2, 2026, with two-year cliff vesting.
Charles River Laboratories International 8-K Report, Regulation FD Disclosure (Dec 3, 2025)
Charles River Laboratories International, Inc. ("Charles River") filed this Current Report on Form 8-K under Item 7.01 (Regulation FD Disclosure) to announce that management will present at the Evercore 8th Annual Healthcare Conference on Wednesday, December 3, 2025, at approximately 10:00 a.m. Eastern time. The filing states that management intends to address certain fourth-quarter demand trends, specifically trends in Discovery and Safety Assessment (DSA) booking activity and related key performance indicators. The key disclosed update is that DSA net book-to-bill has continued to improve each month since the beginning of the third fiscal quarter of 2025. The Company also notes that seasonality during the fourth-quarter holiday period and early January may affect near-term proposal and booking activity, and says it is encouraged by the positive momentum and upward trends since the middle of fiscal 2025. The filing does not provide specific net book-to-bill values, revenue, or earnings figures. The information is furnished rather than filed, so it is not incorporated into Securities Act or Exchange Act filings unless expressly referenced. The filing includes forward-looking statement cautions covering DSA demand, proposal and booking trends, and refers readers to the risk factors in the Company's 2024 Form 10-K and its Form 10-Q for the quarter ended September 27, 2025. The Company disclaims any duty to update these statements except as required by law.
Charles River Laboratories International 8-K Report, Corporate Update (Nov 17, 2025)
Charles River Laboratories International, Inc. (Company) disclosed in a Current Report on Form 8-K under Item 8.01 (Other Events) that the U.S. Securities and Exchange Commission's Division of Enforcement notified the Company on November 14, 2025 that it had concluded its investigation. Based on the information available to the Division, it does not intend to recommend an enforcement action by the SEC against the Company. The SEC inquiry began with a request received on May 16, 2023 for the Company to voluntarily provide information. It was later augmented with a document subpoena and additional inquiries, and related primarily to the sourcing of non-human primates and related disclosures. The Audit Committee had also retained counsel to conduct an independent investigation into certain issues raised in the SEC investigation. The Company stated that its independent investigation has also concluded, with no material findings. For investors, the filing indicates that the matter has been closed without an SEC enforcement recommendation and that the internal review identified no material findings.
Charles River Laboratories International 8-K Report, Financial Results (Nov 5, 2025)
Charles River Laboratories International, Inc. reported third-quarter 2025 results for the quarter ended September 27, 2025, in a press release furnished under Item 2.02 as Exhibit 99.1. Revenue was $1.00 billion, a decrease of 0.5% from $1.01 billion a year earlier. Excluding a 1.3% favorable foreign currency impact and a 0.2% reduction from a divestiture, organic revenue declined 1.6%. GAAP earnings per diluted share were $1.10, compared with $1.33 in the prior-year quarter, primarily due to a $0.33 per share loss from venture capital and other strategic investments. Non-GAAP diluted EPS was $2.43, down 6.2% from $2.59. GAAP operating margin rose to 13.3% from 11.6%, driven by lower restructuring costs, while non-GAAP operating margin eased to 19.7% from 19.9%. By segment, Research Models and Services (RMS) grew revenue 7.9% to $213.5 million, with organic growth of 6.5% driven mainly by large research model products. Discovery and Safety Assessment (DSA) revenue fell 2.3% to $600.7 million, with organic decline of 3.1% on lower discovery and regulated safety assessment volume. Manufacturing Solutions revenue fell 3.1% to $190.7 million, with organic decline of 5.1% led by CDMO and Biologics Testing, partly offset by Microbial Solutions. For 2025, the company narrowed its revenue and non-GAAP EPS guidance to the middle and upper ends of prior ranges, respectively. Reported revenue growth is now guided at (1.5)% to (0.5)%, and non-GAAP EPS at $10.10 to $10.30, versus the prior $9.90 to $10.30. GAAP EPS guidance is $4.15 to $4.35, down from $4.25 to $4.65 previously. Management stated that demand remains stable and some signals suggest the industry may be recovering, but sustained improvement will take time and the company remains cautious.
Charles River Laboratories International Quarterly Report for Q3 Ended Sep 27, 2025
Charles River Laboratories International, Inc. reported third-quarter 2025 revenue of $1,004.9 million, down 0.5% from $1,009.8 million a year earlier, and nine-month revenue of $3,021.2 million, down 0.9%. The filing attributes the declines mainly to lower volume in the DSA and Manufacturing segments, reflecting continued cautious client spending, partly offset by higher RMS revenue, which the filing ties primarily to Noveprim. Operating income rose to $133.8 million (13.3% of revenue) in the quarter from $117.4 million (11.6%), driven by lower severance costs and lower unallocated corporate compensation. For the nine months, operating income fell to $308.6 million (10.2% of revenue) from $395.0 million (13.0%), reflecting accelerated amortization of certain CDMO client relationships after the loss of key customers, higher restructuring and impairment charges, and higher third-party legal and advisory costs. Below the operating line, earnings were pressured by $21.1 million of net losses and impairments on venture capital and strategic equity investments in the quarter. Net income available to common shareholders was $54.4 million for the quarter (diluted EPS of $1.10, versus $1.33) and $132.2 million for the nine months (diluted EPS of $2.65, versus $4.37). The effective tax rate rose to 36.3% in the quarter from 23.0%. Nine-month operating cash flow was $590.1 million, up from $575.2 million. The company repurchased $350.0 million of stock during the nine months and, on October 29, 2025, approved a new $1.0 billion repurchase authorization. Management disclosed that DSA backlog declined to $1.8 billion from $2.0 billion, and that restructuring actions are expected to yield about $225 million of annualized cost savings. In November 2025, the Board announced outcomes of its strategic review, including divesting certain underperforming or non-core assets (about 7% of estimated 2025 revenue) and initiatives expected to generate about $70 million of incremental annual net cost savings, fully realized in 2026. The company also remains subject to an SEC inquiry and securities and derivative litigation related to its non-human primate sourcing, which it says it believes lack merit and plans to defend vigorously.
Charles River Laboratories International 8-K/A Report, Executive Changes (Sep 19, 2025)
Charles River Laboratories International, Inc. filed this Form 8-K/A on September 19, 2025, to amend its Form 8-K filed on September 16, 2025. The original report disclosed the resignation of Flavia H. Pease as Corporate Executive Vice President and Chief Financial Officer, and the appointment of Michael G. Knell as interim Chief Financial Officer. This amendment supplies compensation details for Mr. Knell that had not been determined when the original report was filed. The Compensation Committee of the Company's Board of Directors approved the compensation changes on September 15, 2025, in connection with Mr. Knell's appointment as interim Chief Financial Officer and interim principal financial officer. The package includes an increase in annual base salary to $500,000, effective September 28, 2025; a $10,000 monthly cash payment during his term as interim Chief Financial Officer, effective October 1, 2025; and a one-time grant of restricted stock units with a grant value of $500,000. The restricted stock units are to be granted on November 6, 2025, the first business day after the press release on third-quarter 2025 financial results. Half vest on the first anniversary of the grant date and half on the second anniversary. The filing is signed by Matthew L. Daniel, Corporate Senior Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer.
Charles River Laboratories International 8-K Report, Executive Changes (Sep 16, 2025)
Charles River Laboratories International, Inc. (NYSE: CRL) disclosed that Flavia H. Pease, Corporate Executive Vice President and Chief Financial Officer, informed the company on September 12, 2025 of her intention to resign, effective September 29, 2025. The filing states the resignation is not the result of any disagreement with the company on financial statements, internal control over financial reporting, operations, policies or practices. The press release attached as Exhibit 99.1 says she is leaving to pursue another opportunity. The Board has appointed Michael G. Knell, Corporate Senior Vice President and Chief Accounting Officer, as interim Chief Financial Officer effective upon Ms. Pease's departure, until a permanent successor is named. Mr. Knell, age 49, joined the company in April 2017 and previously served as Chief Accounting Officer and Vice President of Finance at Bruker Corporation from 2012 to 2017. The company has commenced a comprehensive search for a permanent CFO. Information regarding Item 5.02(c)(3) compensation arrangements for Mr. Knell has not yet been determined as of the report date. In the same press release, the company reaffirmed its 2025 revenue and non-GAAP earnings per share guidance, previously provided on August 6, 2025, which it states is supported by its current outlook for third-quarter performance. Chair, President and CEO James C. Foster credited Ms. Pease with helping navigate a challenging demand environment and leading cost-structure initiatives.
Charles River Laboratories International Quarterly Report for Q2 Ended Jun 28, 2025
Charles River Laboratories International, Inc. reported second-quarter 2025 results (three months ended June 28, 2025) with total revenue of $1,032.1 million, up 0.6% from $1,026.1 million a year earlier, while operating income fell to $100.1 million from $151.7 million, and net income attributable to the company's common shareholders decreased to $52.3 million from $90.0 million. For the six months, revenue declined 1.0% to $2,016.3 million and operating income dropped to $174.8 million from $277.6 million. The filing attributes the profit decline mainly to accelerated amortization of certain CDMO client relationships after loss of key customers, higher restructuring and asset impairment charges, and higher third-party legal and advisory costs. DSA revenue declined on cautious client spending, with DSA backlog at $1.9 billion versus $2.0 billion at December 28, 2024. Cash flow from operations improved to $376.3 million for the six months from $323.4 million, while the company repurchased $350.0 million of stock under its $1.0 billion program and had $549.3 million remaining authorization at quarter end. Total debt and finance leases rose to $2.35 billion, and the revolving facility balance increased to $813.0 million from $714.9 million. The company disclosed a Cooperation Agreement with Elliott Investment Management and a comprehensive strategic review overseen by the Board's Strategic Partnership and Capital Allocation Committee, with no assurance the review will produce a transaction. The filing also details ongoing exposure from the non-human primate supply chain matters. The DOJ grand jury and parallel civil investigations were closed, USFWS cleared the Cambodian NHP shipments for entry, and the SEC investigation, a securities class action on appeal, and two stayed derivative lawsuits remain pending, with the company unable to estimate potential losses. The company also cites restructuring actions expected to yield about $225 million in annualized cost savings, of which about $175 million affects fiscal 2025.
Charles River Laboratories International 8-K Report, Financial Results (Aug 6, 2025)
Charles River Laboratories International, Inc. reported second-quarter 2025 results for the quarter ended June 28, 2025, in a press release furnished as Exhibit 99.1 to this Form 8-K dated August 6, 2025. Total revenue was $1,032.1 million, up 0.6% from $1,026.1 million a year earlier, with organic revenue declining 0.5% after a 1.2% foreign currency benefit. GAAP net income available to common shareholders was $52.3 million, or $1.06 per diluted share, versus $1.74 a year earlier, driven mainly by accelerated amortization of certain CDMO client relationships, restructuring costs, and third-party legal and advisory costs. Non-GAAP diluted EPS rose 11.4% to $3.12 from $2.80, and non-GAAP operating margin improved to 22.1% from 21.3%. The Discovery and Safety Assessment (DSA) segment, the largest by revenue at $618.0 million, saw organic revenue decline 2.4%, while Research Models and Services (RMS) grew organically 2.3% and Manufacturing Solutions grew organically 2.9%. Management said biopharmaceutical demand is stabilizing and that DSA results were better than initially expected. The company also reported that the U.S. Department of Justice had closed the grand jury and parallel civil investigations relating to non-human primate shipments from late 2022 and early 2023. The company raised its full-year 2025 guidance. Reported revenue growth is now expected to be (2.5)% to (0.5)%, up from (5.5)% to (3.5)%, and organic revenue growth is now (3.0)% to (1.0)%, up from (4.5)% to (2.5)%. GAAP EPS estimate is $4.25 to $4.65, and non-GAAP EPS estimate is $9.90 to $10.30, up from $9.30 to $9.80.
Charles River Laboratories International 8-K Report, Executive Changes (May 23, 2025)
Charles River Laboratories International, Inc. filed this Current Report on Form 8-K to disclose two matters: an employment agreement amendment for its Chair, President and Chief Executive Officer, and the results of its 2025 Annual Meeting of Shareholders held on May 20, 2025. On May 20, 2025, the Company and James C. Foster entered into Amendment No. 1 to his Amended and Restated Employment Agreement dated May 18, 2021. The amendment extends his employment term by one year, to February 12, 2027, and leaves all other terms unchanged. The Company states that the full amendment will be filed as an exhibit to its Quarterly Report on Form 10-Q for the second quarter of fiscal 2025. At the Annual Meeting, shareholders elected seven directors to serve until the 2026 Annual Meeting. Mr. Foster received 39,676,718 votes for and 1,908,059 against, while the other six nominees each received more than 40 million votes for. Shareholders approved, on an advisory basis, the compensation of the named executive officers, with 40,218,870 votes for, 1,432,240 against and 102,252 abstaining. Shareholders also ratified PricewaterhouseCoopers LLP as independent auditors, with 42,348,057 votes for and 1,551,238 against. A shareholder proposal submitted by PETA to publish a report on non-human primates imported by the Company was not approved, receiving 3,457,547 votes for and 38,051,509 against. Board composition also changed. Robert Bertolini, Deborah T. Kochevar, George E. Massaro and Richard F. Wallman did not stand for re-election after their terms expired, as previously disclosed in a Form 8-K filed May 7, 2025. On May 20, 2025, the Board appointed Steven Barg, Mark Enyedy, Abraham Ceesay and Paul Graves to fill the resulting four vacancies, each with a term expiring at the 2026 Annual Meeting.
Charles River Laboratories International 8-K Report, Material Agreement (May 7, 2025)
On May 6, 2025, Charles River Laboratories International, Inc. entered into a Cooperation Agreement with Elliott Investment Management L.P., Elliott Associates, L.P. and Elliott International, L.P. (the Elliott Parties), effective that date. Under the agreement, the company will appoint Steven Barg, Mark Enyedy, Abraham Ceesay and Paul Graves to its Board of Directors effective following the 2025 Annual Meeting, each with a term expiring at the 2026 Annual Meeting. Four incumbent directors, Robert Bertolini, Deborah T. Kochevar, George E. Massaro and Richard F. Wallman, will not stand for re-election at the 2025 Annual Meeting, which is scheduled for May 20, 2025. The company also agreed to appoint at least one Investor Designated Director to the Strategic Partnership and Capital Allocation Committee, the Compensation Committee and the Corporate Governance and Nominating Committee, and to limit the Board to no more than 11 members until the Cooperation Period expires. The Board, through the Strategic Committee, will conduct a comprehensive review and evaluation of the company's business and prospects, including an examination of various alternatives to enhance long-term stockholder value. The Cooperation Agreement includes voting commitments, customary standstill restrictions and mutual non-disparagement provisions. The Cooperation Period runs until the later of 30 calendar days before the advance notice deadline for 2026 Annual Meeting nominations and the day an Investor Director ceases to serve on the Board. The company's press release states that Elliott is its largest investor and that the Board will have eleven directors, nine of whom will be independent. The press release also states that Elliott's partner said the company's current value is significantly disconnected from its underlying potential. Items 5.02(d) and 1.01 describe committee assignments and a non-employee director initial equity award valued at $255,500 before pro-rata adjustment, split 50% restricted stock or units and 50% stock options. The filing is signed by Matthew L. Daniel, Corporate Senior Vice President, General Counsel, Corporate Secretary & Chief Compliance Officer.
Charles River Laboratories International 8-K Report, Financial Results (May 7, 2025)
Charles River Laboratories International, Inc. reported first-quarter 2025 results, with total revenue of $984.2 million, down 2.7% from $1,011.6 million in the first quarter of 2024. Organic revenue decreased 1.8%, with declines in all three business segments. GAAP net income available to common shareholders was $25.5 million, or $0.50 per diluted share, compared with $1.30 per diluted share a year earlier. The GAAP decline was driven by lower revenue and accelerated amortization of certain CDMO client relationships, which raised amortization of intangible assets to $65.3 million from $32.6 million. Non-GAAP diluted EPS was $2.34, up 3.1% from $2.27, helped mainly by lower tax rates, interest expense and diluted share count. The company increased its 2025 guidance, now projecting reported revenue decline of (5.5)% to (3.5)% and GAAP EPS of $4.35 to $4.85, versus prior ranges of (7.0)% to (4.5)% and $4.30 to $4.80. Non-GAAP EPS guidance rose to $9.30 to $9.80 from $9.10 to $9.60. Management attributed the raise primarily to improved DSA net bookings in the first quarter, which are expected to add DSA revenue this year, particularly in the first half. CEO James C. Foster described the quarter as showing signs of demand stabilization, with DSA bookings at their highest level in two years, while maintaining a balanced yet cautious outlook. Capital allocation was active: the company repurchased 2.1 million shares for $350.0 million in the quarter and had $549.3 million remaining under its $1.0 billion authorization as of March 29, 2025. Long-term debt, net and finance leases rose to $2.51 billion from $2.24 billion at year-end 2024. The filing also notes ongoing third-party legal costs in the DSA segment tied to U.S. government investigations into the NHP supply chain, which the company excludes from non-GAAP results.
Charles River Laboratories International Quarterly Report for Q1 Ended Mar 29, 2025
Charles River Laboratories International, Inc. reported first-quarter 2025 results (three months ended March 29, 2025) with total revenue of $984.2 million, down $27.4 million, or 2.7%, from $1,011.6 million a year earlier. The decline was driven mainly by lower volume in the DSA segment, where clients continued to spend cautiously, with smaller declines in RMS and Manufacturing. Operating income fell to $74.7 million (7.6% of revenue) from $126.0 million (12.5%), reflecting lower revenue, $65.3 million of intangible amortization (including $35.5 million of accelerated amortization tied to lost key CDMO customers), restructuring charges of $23.8 million, and third-party legal costs in DSA. Net income attributable to the company's common shareholders declined to $25.5 million, or $0.50 per diluted share, from $67.3 million, or $1.30 per diluted share. Cash generation improved, with operating cash flow of $171.7 million versus $129.9 million, helped by lower variable compensation payments and favorable supplier payment timing. The company spent $350.0 million repurchasing 2.1 million shares under its $1.0 billion authorization, leaving $549.3 million available, and net revolving credit facility borrowings of $267.5 million raised total debt and finance leases to $2.53 billion. Cash and cash equivalents were $229.4 million at quarter-end, and the company reports that it believes existing funds and financing access are sufficient for the foreseeable future. The filing also flags ongoing risks: U.S. DOJ, USFWS, and SEC investigations into non-human primate sourcing, securities and derivative lawsuits, new tariffs affecting supply from Vietnam, Mauritius, and China, and reduced NIH funding and FDA moves to reduce animal testing. On May 6, 2025, the company entered a Cooperation Agreement with a large shareholder and agreed to a comprehensive strategic review overseen by the Strategic Partnership and Capital Allocation Committee.
Charles River Laboratories International 8-K Report, Corporate Update (Feb 21, 2025)
Charles River Laboratories International, Inc. (the "Company") disclosed in this Form 8-K, filed February 21, 2025, that Chair, President and CEO James C. Foster and Corporate Executive Vice President and Chief Operating Officer Birgit Girshick each bought shares of Company common stock in open market transactions on February 20, 2025. Mr. Foster purchased 6,075 shares at an average price of $165.01, for an aggregate purchase price of approximately $1 million. Ms. Girshick purchased 1,514 shares at an average price of $164.63, for an aggregate purchase price of approximately $250,000. Both executives said the purchases reflect their confidence in the Company's strategic direction and long-term growth prospects. Before making these purchases, both executives terminated their Rule 10b5-1 trading plans on February 19, 2025, so that the buys would not unintentionally violate Section 16 short-swing profit rules through open market sales within six months of purchases. Mr. Foster's terminated plan, dated February 26, 2024, allowed for the sale of a maximum of 129,721 shares, and he sold 25,000 shares under it on August 1, 2024. Ms. Girshick's terminated plan, dated November 22, 2023, allowed for the sale of a maximum of 22,362 shares, and the filing states she did not sell any shares under it. The purchases will be reported separately on Forms 4. The filing is an Item 8.01 (Other Events) disclosure and contains no financial results, guidance, or operational updates. It refers to the Company's Annual Report on Form 10-K filed February 19, 2025, for risks relating to the Company, and includes standard forward-looking statement language.
Charles River Laboratories International Annual Report, Year Ended Dec 28, 2024
Charles River Laboratories International, Inc. reported fiscal 2024 total revenue of $4.05 billion, down from $4.13 billion in fiscal 2023, a decrease of $79.4 million, or 1.9%, driven mainly by lower volume in its DSA business amid more cautious biopharmaceutical client spending. Operating income fell to $227.3 million (5.6% operating margin) from $617.3 million (14.9%), reflecting a $215.0 million goodwill impairment in the Biologics Solutions reporting unit, restructuring charges of $107.0 million, and a $27 million inventory charge tied to the non-human primate investigations. Net income available to common shareholders dropped to $10.3 million, or $0.20 per diluted share, from $474.6 million, or $9.22 per diluted share, in 2023. Cash flow from operations was $734.6 million, and the company ended the year with $2.2 billion of debt and finance leases. Management expects restructuring actions to yield approximately $225 million of annualized cost savings and plans to close or consolidate about 15 additional sites over the next two years. The company repurchased $100.7 million of stock in 2024, had $899.3 million remaining under its authorization, and intends to repurchase about $350 million in 2025. The Credit Facility was reduced from $3.0 billion to $2.0 billion and extended to December 2029. The filing also highlights significant legal and regulatory exposure. U.S. DOJ and USFWS investigations into non-human primate shipments from Cambodia remain ongoing, with a parallel SEC inquiry, and a putative securities class action was dismissed in July 2024 and is on appeal. Two derivative lawsuits are stayed pending that appeal. The company also disclosed a January 2025 CDMO client complete response letter and an FDA Form 483 at a Company facility, and noted that the NIH's February 7, 2025 indirect-cost policy has been temporarily stayed.
Charles River Laboratories International 8-K Report, Financial Results (Feb 19, 2025)
Charles River Laboratories International, Inc. (NYSE: CRL) reported fourth-quarter 2024 revenue of $1.00 billion, a decrease of 1.1% from $1.01 billion in the fourth quarter of 2023, with organic revenue down 1.8%. The company recorded a non-cash goodwill impairment of $215.0 million in the quarter related to its Biologics Solutions reporting unit, producing a GAAP net loss available to common shareholders of $(215.7) million, or $(4.22) per share. On a non-GAAP basis, fourth-quarter diluted earnings per share rose 8.1% to $2.66 from $2.46, driven by higher operating income and favorable below-the-line items. For full-year 2024, revenue decreased 1.9% to $4.05 billion from $4.13 billion, with organic revenue down 2.8%. GAAP diluted EPS was $0.20, down from $9.22 in 2023, while non-GAAP diluted EPS was $10.32, down 3.3% from $10.67. Segment results were mixed: Research Models and Services and Manufacturing Solutions grew full-year revenue, while Discovery and Safety Assessment revenue declined 6.3%. For 2025, management guides reported revenue growth of (7.0)% to (4.5)% and GAAP EPS of $4.30 to $4.80, with non-GAAP EPS of $9.10 to $9.60. The company expects DSA pricing to be a headwind throughout 2025, lower commercial CDMO revenue to weigh on Manufacturing growth, and plans to repurchase approximately $350 million of common stock in 2025.
Charles River Laboratories International 8-K Report, Regulation FD Disclosure (Jan 14, 2025)
Charles River Laboratories International, Inc. furnished this Form 8-K under Item 7.01 (Regulation FD) ahead of a presentation at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025, at approximately 5:15 p.m. Eastern time. The company posted a slide presentation that offers a preliminary assessment of its 2025 outlook. It expects 2025 revenue to decline organically in a similar range to its estimated 2024 decline, with constrained spending from global biopharma clients due to restructuring programs and pipeline reprioritization. It expects non-GAAP operating margin to be modestly below the estimated 2024 level, as cost savings can protect margin but cannot fully offset lower revenue. Full 2025 guidance is planned for release with fourth-quarter 2024 results in mid-February 2025. In its Discovery and Safety Assessment (DSA) segment, biotech demand key performance indicators stabilized in 2024 and gradually improved year over year. Global biopharma demand stabilized in the second half of 2024 after meaningful deterioration during the second quarter, and the company expects current trends to persist into 2025 and continue to pressure year-over-year growth rates. DSA pricing is expected to be a revenue headwind in 2025. The filing flags material pressure in the contract development and manufacturing organization (CDMO) business. A cell therapy client has reevaluated its manufacturing network and notified the company that it will terminate its commercial agreement, and the company expects lower commercial revenue from another cell therapy client. The company states that it is currently assessing the recoverability of goodwill and long-lived assets for a potential impairment.
Charles River Laboratories International 8-K Report, Financial Obligation (Dec 13, 2024)
On December 13, 2024, Charles River Laboratories International, Inc. ("Charles River") entered into its Tenth Amended and Restated Credit Agreement with certain financial institutions and JPMorgan Chase Bank, N.A., as administrative agent. The amendment extends the maturity date for the facilities, reduces aggregate revolving commitments from $3 billion to $2 billion, adds Charles River Laboratories, Inc. ("CRL"), a direct subsidiary, as a borrower, and makes other changes to covenants and terms. The revolving facility provides up to approximately $2 billion, is available in U.S. dollars to Charles River and CRL and in euros and sterling to certain subsidiaries in the United Kingdom, the Netherlands and Luxembourg, and matures on December 13, 2029, with no scheduled payments required before that date. Borrowings bear interest at base rate, Term SOFR, EURIBOR or daily simple RFR rates, plus a margin based on Charles River's leverage ratio. Obligations are guaranteed by CRL and secured by substantially all assets of Charles River, CRL and future material domestic subsidiaries, including a pledge of 100% of the capital stock of CRL and future material domestic subsidiaries and 65% of the capital stock of certain first-tier material foreign subsidiaries. The agreement requires compliance with an interest coverage ratio test and a leverage ratio test and includes negative covenants limiting additional indebtedness, liens, investments, mergers and acquisitions, asset sales, subsidiary distribution restrictions, affiliate transactions and changes to the business. The full agreement is filed as Exhibit 10.1 and incorporated by reference.
Charles River Laboratories International Quarterly Report for Q3 Ended Sep 28, 2024
Charles River Laboratories International, Inc.'s Form 10-Q for the quarter ended September 28, 2024 shows total revenue of $1,009.8 million for the three months, down $16.9 million or 1.6% from $1,026.6 million a year earlier, and $3,047.4 million for the nine months, down $68.5 million or 2.2%. The decline was driven mainly by lower volume in the DSA segment, partly offset by growth in Manufacturing and the Noveprim acquisition. Operating income fell to $117.4 million (11.6% of revenue) for the quarter from $151.5 million, and to $395.0 million (13.0% of revenue) for the nine months from $484.3 million. The filing attributes the drop mainly to lower revenue and restructuring charges of $30.6 million in the quarter and $65.6 million year to date. Net income attributable to common shareholders was $68.7 million for the quarter (diluted EPS $1.33) and $226.0 million for the nine months (diluted EPS $4.37). Cash flow from operations improved to $575.2 million for the nine months, up from $463.0 million, while capital expenditures fell to $157.4 million from $240.2 million. Long-term debt, net and finance leases declined to $2.33 billion from $2.65 billion, mainly from net repayments on the revolving facility. The company repurchased 0.5 million shares for $100.7 million under a new $1.0 billion authorization approved August 2, 2024, leaving $899.3 million available. The filing also reports that the company is cooperating with U.S. DOJ, USFWS and SEC investigations into its non-human primate supply chain, and that a putative securities class action was dismissed in July 2024 and is on appeal. The company says it cannot estimate the potential exposure from these matters. In the DSA segment, the Discovery Services goodwill reporting unit's fair value exceeded its carrying value by approximately 22%, and no impairment was recognized.
Charles River Laboratories International 8-K Report, Financial Results (Nov 6, 2024)
Charles River Laboratories International, Inc. reported third-quarter 2024 results for the quarter ended September 28, 2024. Revenue was $1.01 billion, a decrease of 1.6% from $1.03 billion a year earlier, or a 2.7% decline on an organic basis. GAAP diluted earnings per share were $1.33, compared with $1.69 in the third quarter of 2023, while non-GAAP diluted earnings per share were $2.59, compared with $2.72. The GAAP operating margin fell to 11.6% from 14.8%, mainly due to restructuring costs, and the non-GAAP operating margin declined to 19.9% from 20.5%, as improvements in all three segments were offset by higher unallocated corporate costs. Segment results were mixed. Research Models and Services revenue rose 5.9% to $197.8 million, aided by the Noveprim acquisition, and Manufacturing Solutions revenue rose 12.0% to $196.9 million, with organic growth of 11.8%. Discovery and Safety Assessment revenue fell 7.4% to $615.1 million, driven by lower volume in both Discovery Services and Safety Assessment. Management said demand indicators were relatively stable in the quarter and that biotech funding had improved in 2024, though clients are still reducing spending during restructuring and pipeline reprioritization. The company narrowed and slightly raised its non-GAAP EPS guidance to $10.10 to $10.30 and lowered its GAAP EPS guidance to $5.30 to $5.50. Reported revenue growth guidance is now (3.0)% to (2.0)%. The company also authorized a new $1.0 billion stock repurchase program in August 2024, repurchased $100.7 million of shares in the third quarter, and had $899.3 million remaining under that authorization as of September 28, 2024.
Charles River Laboratories International Quarterly Report for Q2 Ended Jun 29, 2024
Charles River Laboratories International, Inc. reported a quarter ended June 29, 2024 with total revenue of $1,026.1 million, down from $1,059.9 million in the prior-year quarter, a decrease of $33.8 million or 3.2%. The filing attributes the decline primarily to lower volume in the DSA business, partially offset by higher Manufacturing revenue and the Noveprim acquisition. Operating income fell to $151.7 million (14.8% margin) from $164.9 million (15.6%), and net income available to common shareholders decreased to $90.0 million from $97.0 million. For the six months, revenue was $2,037.7 million, down 2.5%, and operating income was $277.6 million versus $332.8 million, with restructuring charges of $35.0 million in the period. Cash flow from operations improved to $323.4 million for the six months from $257.5 million, driven by working capital improvements. Cash and cash equivalents fell to $179.2 million, and long-term debt, net and finance leases declined to $2,409.4 million from $2,647.1 million as the revolving facility was paid down. DSA backlog decreased to $2.2 billion from $2.5 billion, and management cited a more cautious spending environment among biopharmaceutical clients. The company expects restructuring actions to yield more than $150 million in annualized cost savings, of which about $100 million affects fiscal 2024. The filing also details ongoing U.S. government investigations into non-human primate sourcing, a securities class action that was dismissed on July 1, 2024 and is now under appeal, and derivative lawsuits, with the company stating it cannot reasonably estimate potential exposure. On August 2, 2024, the Board approved a new $1.0 billion stock repurchase authorization replacing the prior program, which had $129.1 million remaining.
Charles River Laboratories International 8-K Report, Financial Results (Aug 7, 2024)
Charles River Laboratories International, Inc. (NYSE: CRL) reported second-quarter 2024 results on August 7, 2024 (quarter ended June 29, 2024). Revenue was $1.03 billion, down 3.2% from $1.06 billion a year earlier, with organic revenue also declining 3.2%. GAAP diluted EPS was $1.74, down 7.9% from $1.89, while non-GAAP diluted EPS rose 4.1% to $2.80 from $2.69, driven mainly by lower performance-based compensation accruals and higher Manufacturing Solutions revenue and operating income. The Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) segments both declined on an organic basis, at 5.0% and 3.9% respectively, while Manufacturing Solutions grew 3.7% organically. The company materially cut its 2024 outlook. Reported revenue growth guidance is now (4.5)% to (2.5)%, down from 1.0% to 4.0%, and organic growth is now (5.0)% to (3.0)%, versus 0.0% to 3.0% previously. GAAP EPS guidance fell to $5.65–$5.95 from $7.60–$8.10, and non-GAAP EPS guidance fell to $9.90–$10.20 from $10.90–$11.40. Management attributed the revision to a lack of demand recovery from small and mid-sized biotech clients and softer trends from global biopharmaceutical clients, and said it no longer expects demand to improve in the second half of 2024. To address this, the Board approved a new $1.0 billion stock repurchase authorization, replacing a prior $1.3 billion program that had $129.1 million remaining when terminated. Restructuring initiatives are expected to yield annualized cost savings of over $150 million (including actions taken since last year through Q3 2024), with approximately $100 million realized in 2024.
Charles River Laboratories International 8-K Report, Shareholder Vote Results (May 10, 2024)
Charles River Laboratories International, Inc. held its Annual Meeting of Shareholders on May 8, 2024, and this Current Report on Item 5.07 reports the voting results. Shareholders elected all eleven director nominees to serve until the 2025 Annual Meeting. Shareholders also approved, on an advisory, non-binding basis, the compensation of the named executive officers, with 43,833,503 votes for, 2,299,362 against, 55,335 abstaining and 2,038,517 broker non-votes. Shareholders ratified the appointment of PricewaterhouseCoopers LLP as independent auditors for fiscal 2024, with 45,612,837 votes for and 2,586,704 against. Shareholders did not approve the shareholder proposal submitted by PETA to publish a report on non-human primates imported by the Company, which received 11,428,432 votes for and 34,538,572 against. The filing states that the proposals are described in the Company's proxy statement dated March 29, 2024, and that Computershare Trust Company, N.A. served as independent proxy tabulator and Inspector of Election.
Charles River Laboratories International 8-K Report, Financial Results (May 9, 2024)
Charles River Laboratories International, Inc. filed a Current Report on Form 8-K on May 9, 2024, under Item 2.02 (Results of Operations and Financial Condition) to report its financial results for the first quarter ended March 30, 2024. The results are presented in a press release dated May 9, 2024, filed as Exhibit 99.1. Under Item 2.02, the information is furnished rather than filed, so it is not subject to Section 18 of the Exchange Act and is not incorporated by reference into Securities Act or Exchange Act filings unless expressly referenced. The press release contains forward-looking statements covered by the safe harbor language of the Private Securities Litigation Reform Act of 1995. The company states that the risks relating to those statements are set forth in its filings with the Securities and Exchange Commission. Investors should review those filings alongside the press release to understand the risk factors that could cause actual results to differ from the forward-looking statements. The filing also includes Exhibit 104, the Cover Page Interactive Data File embedded within the Inline XBRL document.
Charles River Laboratories International Quarterly Report for Q1 Ended Mar 30, 2024
Charles River Laboratories International, Inc. reported total revenue of $1,011.6 million for the three months ended March 30, 2024, down $17.8 million, or 1.7%, from $1,029.4 million in the prior-year quarter. The decline was driven mainly by lower volume in the DSA segment, partly offset by higher RMS revenue (including the Noveprim acquisition) and higher Manufacturing revenue. Operating income fell to $126.0 million, a 12.5% operating margin, versus $167.9 million and 16.3% a year earlier, reflecting lower revenue, higher staffing and operating costs, and restructuring charges of about $17 million. Net income available to common shareholders decreased to $73.0 million from $103.1 million, though diluted EPS as presented was $1.30 versus $2.01 after noncontrolling interest and dividend adjustments. Cash flow from operations improved to $129.9 million from $109.4 million, driven by timing of vendor payments and improvements in revenue-related accounts. Total debt and finance leases were $2.68 billion at quarter end, with cash and cash equivalents of $327.0 million. The company repurchased no shares under its $1.3 billion program during the quarter, leaving $129.1 million authorized, and management stated the company believes existing funds are sufficient for foreseeable operations. The filing also details ongoing U.S. government investigations by the DOJ, USFWS and SEC related to non-human primate shipments from Cambodia, a securities class action, and a derivative lawsuit. The company states it believes the concerns are without merit, cannot predict outcomes, and cannot reasonably estimate potential exposure for the class action or derivative suit. Inventory tied to the Cambodia-sourced shipments was approximately $27 million.
Charles River Laboratories International 8-K Report, Financial Results (Feb 14, 2024)
Charles River Laboratories International, Inc. reported fourth-quarter and full-year 2023 results and provided 2024 guidance in a press release furnished under Item 2.02. Fourth-quarter revenue was $1.01 billion, versus $1.10 billion in the fourth quarter of 2022, and the filing states organic revenue decreased 3.5%. Fourth-quarter GAAP diluted EPS was $3.62 and non-GAAP diluted EPS was $2.46, with GAAP EPS boosted by a $2.04 per share gain on venture capital and strategic investments, including the Noveprim Group investment. For full-year 2023, revenue rose 3.9% to $4.13 billion, organic revenue grew 6.5%, GAAP diluted EPS was $9.22, and non-GAAP diluted EPS was $10.67. Management described the 2024 demand environment as cautious and said it believes the current market environment is transitory, expecting constrained client spending to persist in 2024 but stabilizing over the year. The company guided 2024 reported revenue growth of 1.0% to 4.0%, organic growth of 0.0% to 3.0%, GAAP EPS of $7.90 to $8.40, and non-GAAP EPS of $10.90 to $11.40. The outlook assumes Noveprim contributes at least $0.30 to non-GAAP EPS. The filing also details the November 30, 2023 acquisition of an additional 41% stake in Noveprim Group, bringing its controlling interest to 90%, for $144.6 million plus up to $55.0 million in contingent payments and $12.0 million in deferred payments. Segment results were mixed: Discovery and Safety Assessment organic revenue fell 6.0% in the fourth quarter on a Discovery Services decline, while Manufacturing organic revenue grew 2.3%.
Charles River Laboratories International Annual Report, Year Ended Dec 30, 2023
Charles River Laboratories International, Inc. (CRL) reported fiscal 2023 total revenue of $4.13 billion, up from $3.98 billion in 2022, an increase of $153.3 million or 3.9%, driven mainly by Safety Assessment volume and pricing and the Explora BioLabs acquisition, partially offset by the Avian divestiture. Operating income declined to $617.3 million (14.9% margin) from $651.0 million (16.4%), reflecting higher Manufacturing operating costs, restructuring and asset impairment charges, and the Avian divestiture. Net income attributable to common shareholders was $474.6 million, versus $486.2 million in 2022, while cash flow from operations rose to $683.9 million from $619.6 million. Segment revenue was RMS $792.3 million, DSA $2.62 billion (63.3% of total revenue), and Manufacturing $721.4 million. The filing highlights several risks. Non-human primate supply is constrained after the company voluntarily suspended shipments of Cambodia-sourced primates into the U.S. amid a DOJ and USFWS grand jury and civil investigation, an SEC inquiry, a putative securities class action and a derivative lawsuit. The company says it cannot predict the timing or outcome of these matters, including potential fines or liabilities. Total debt and finance leases were $2.6 billion, and the company completed the Noveprim acquisition, which lifted its stake to 90%. Discovery Services demand declined and DSA backlog fell to $2.45 billion from $3.15 billion. Restructuring charges were about $30 million, with expected annualized savings of $60 million to $70 million. The company had $129.1 million remaining under its $1.3 billion stock repurchase authorization and did not repurchase shares in the fourth quarter. It paid no cash dividends in 2023 and does not plan to in the coming year.
Charles River Laboratories International 8-K Report, Executive Changes (Jan 24, 2024)
Charles River Laboratories International, Inc. filed this Form 8-K under Item 5.02 to report a board change. Effective January 22, 2024, the Board increased its size from eleven to twelve members and then filled the new vacancy by appointing Ms. Reshema Kemps-Polanco as a director. The filing states she has been appointed to the existing Compensation Committee and Strategic Planning and Capital Allocation Committee. The filing states there are no arrangements or understandings under which she was selected as a director, and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K. She will participate in the non-employee director compensation program. Under that program, the annual equity award before pro-rata adjustment is valued at $255,500, split 50% restricted stock units and 50% stock options, issued on the first day of the month following her appointment. New directors appointed after the Annual Meeting also receive an initial equity award and cash retainer on a pro-rata basis. Ms. Kemps-Polanco has 25 years of pharmaceutical industry experience and is currently Executive Vice President and Chief Commercial Officer of Novartis US. Her prior roles include several leadership positions at Johnson & Johnson from 2014 to 2021, and she began her career at Novartis in sales. For investors, the filing is primarily a governance update with a new independent director and no financial results disclosed.
Charles River Laboratories International 8-K Report, Executive Changes (Jan 16, 2024)
Charles River Laboratories International, Inc. (CRL) filed this Current Report under Item 5.02, which covers departures and appointments of certain officers. The Company announced on January 9 that William D. Barbo, Corporate Executive Vice President and Chief Commercial Officer, will retire at the end of 2024 after a 42-year career with the Company. Until then, he will continue as Executive Vice President and strategic advisor to ensure a smooth transition of his responsibilities. In connection with the planned retirement, Kristen Eisenhauer is assuming the role of Senior Vice President, Chief Commercial Officer. Ms. Eisenhauer has been with the Company for 20 years and has held leadership roles spanning operations management, client services, sales, and marketing. Most recently, she served as Corporate Senior Vice President, Safety Assessment Customer Excellence. For investors, the filing is a planned leadership succession in the commercial function. It discloses no financial results, guidance, or compensation terms for either executive.
Charles River Laboratories International 8-K Report, Corporate Update (Nov 15, 2023)
Charles River Laboratories International, Inc. filed this Form 8-K on November 15, 2023 under Item 8.01 (Other Events) to disclose two related actions by Chair, President and Chief Executive Officer James C. Foster. On November 14, 2023, Mr. Foster purchased 5,620 shares of the Company's common stock at an average price of $178.05, for an aggregate purchase price of approximately $1.0 million, in open market transactions. He described the purchases as reflecting his confidence in the Company's strategic direction and long-term growth prospects. His purchases will be reported separately on a Form 4. On the same day, Mr. Foster terminated his Rule 10b5-1 Trading Plan dated February 24, 2023, which had allowed for the sale of up to 112,341 shares under a pre-established formula. The filing states he terminated the plan to facilitate the purchases without unintentionally violating the short-swing profit rules of Section 16 of the Securities Exchange Act of 1934, which would have been triggered by open market sales within six months of open market purchases. The filing states that Mr. Foster did not sell any shares under the Plan. The filing is primarily an insider-activity disclosure and contains no financial results or operating metrics. It includes standard forward-looking statement safe-harbor language and references the Company's Annual Report on Form 10-K filed February 16, 2022.
Charles River Laboratories International 8-K Report, Financial Results (Nov 8, 2023)
Charles River Laboratories International, Inc. (NYSE: CRL) reported third-quarter 2023 results on November 8, 2023. Total revenue was $1.03 billion, up 3.8% from $989.2 million in the third quarter of 2022, with organic revenue growth of 4.1%. GAAP net income attributable to common shareholders was $87.4 million, down 9.4% year over year, and GAAP diluted EPS was $1.69, down 10.1% from $1.88. Non-GAAP net income rose 4.2% to $140.5 million and non-GAAP diluted EPS rose 3.4% to $2.72. The company attributed the GAAP decline mainly to site consolidation and associated costs, a loss on certain venture capital and other strategic investments, higher interest expense, and a higher tax rate. Management said third-quarter results exceeded its expectations and that early signs of more favorable demand trends were emerging, including a sequential improvement in the Safety Assessment cancellation rate. However, client spending patterns continued to pressure the Research Models and Services (RMS) segment and the Microbial Solutions business. The company said it is aligning its cost structure with the current pace of demand. Charles River updated its 2023 guidance, narrowing revenue growth and non-GAAP EPS ranges. Reported revenue growth guidance is now 2.5% to 3.5% (previously 2.5% to 4.5%), and non-GAAP EPS guidance is $10.50 to $10.70 (previously $10.30 to $10.90). GAAP EPS guidance was lowered to $7.30 to $7.50 from $7.60 to $8.20. The company described the changes as reflecting a shift in the timing of results in the second half of the year.
Charles River Laboratories International Quarterly Report for Q3 Ended Sep 30, 2023
Charles River Laboratories International, Inc. reported third-quarter 2023 total revenue of $1,026.6 million, up from $989.2 million in the prior-year quarter, an increase of 3.8%. Growth was driven mainly by higher volume and pricing in the Safety Assessment business, partially offset by the divestiture of the Avian Vaccine Services business. Operating income was essentially flat at $151.5 million, with operating margin falling to 14.8% from 15.3%, reflecting higher Manufacturing operating costs, restructuring and asset impairment charges, and the Avian divestiture. Net income attributable to common shareholders declined to $87.4 million from $96.5 million, mainly due to higher interest expense from higher rates on variable-rate debt. For the nine months ended September 30, 2023, total revenue was $3,115.9 million, up 8.3%, and net income attributable to common shareholders was $287.5 million versus $298.8 million a year earlier. Net cash provided by operating activities rose to $463.0 million from $384.9 million. The DSA backlog decreased to $2.60 billion from $3.15 billion at December 31, 2022, and management described a more cautious client spending environment, though it noted sequential improvement in the DSA net book-to-bill ratio and study cancellation rate in the third quarter. The filing also details ongoing U.S. government investigations by the DOJ, USFWS and SEC into the company's non-human primate supply chain, including shipments from Cambodia, and a putative securities class action filed May 19, 2023. The company states it believes the concerns and the class action are without merit, and it cannot predict the outcome or estimate potential exposure. The company also agreed to acquire an additional 41% equity stake in a DSA supplier for a preliminary price of $143 million in cash, with closing subject to regulatory approval.
Charles River Laboratories International Quarterly Report for Q3 Ended Jul 1, 2023
Charles River Laboratories International, Inc. reported second-quarter 2023 results in this Form 10-Q for the period ended July 1, 2023. Total revenue for the three months rose to $1,059.9 million from $973.1 million, an increase of 8.9%, driven mainly by Safety Assessment volume and pricing and the Explora BioLabs acquisition, partly offset by the Avian divestiture. Operating income fell to $164.9 million from $187.4 million, with operating margin of 15.6% versus 19.3%, mainly because of lower Manufacturing segment operating income, particularly in Biologics Solutions. Net income attributable to common shareholders was $97.0 million, or $1.89 per diluted share, compared with $109.3 million, or $2.13, a year earlier. Interest expense rose sharply to $35.0 million from $3.7 million, reflecting higher interest rates on variable-rate debt. Cash flow from operations for the six months was $257.5 million, versus $252.1 million a year earlier. The company's DSA backlog declined to $2.76 billion from $3.15 billion at December 31, 2022, and management described a more cautious spending environment from biopharmaceutical clients. Total debt and finance leases were $2.70 billion at July 1, 2023, and the company had $129.1 million remaining under its $1.3 billion stock repurchase program. In the first half, it did not repurchase shares under that program. The filing also details significant legal and regulatory exposure. The U.S. Department of Justice and U.S. Fish and Wildlife Service are investigating shipments of non-human primates from Cambodia, the company has voluntarily suspended such shipments, and the SEC has made an inquiry. A putative securities class action was filed on May 19, 2023. The company states it cannot predict the outcome or estimate the range of possible loss. It also agreed on July 28, 2023 to acquire an additional 41% stake in a DSA supplier for $143 million in cash, plus contingent payments of up to $55 million, subject to regulatory approval.
Charles River Laboratories International 8-K Report, Financial Results (Aug 9, 2023)
Charles River Laboratories International, Inc. (NYSE: CRL) reported second-quarter 2023 results for the quarter ended July 1, 2023, as disclosed in Exhibit 99.1, a press release dated August 9, 2023. Revenue was $1.06 billion, up 8.9% from $973.1 million a year earlier, with organic revenue growth of 11.2% driven primarily by the Research Models and Services (RMS) and Discovery and Safety Assessment (DSA) segments. The Avian Vaccine divestiture reduced reported growth by 2.3%. GAAP net income attributable to common shareholders was $97.0 million, or $1.89 diluted EPS, down 11.3% from $2.13, while non-GAAP net income was $138.3 million, or $2.69 diluted EPS, down 2.9% from $2.77. The company attributed the lower earnings mainly to non-operating items, including higher interest expense and a higher tax rate, as well as the Avian divestiture. The company narrowed its 2023 guidance to the upper ends of prior ranges, now projecting reported revenue growth of 2.5% to 4.5% and non-GAAP EPS of $10.30 to $10.90 (previously $9.90 to $10.90) and GAAP EPS of $7.60 to $8.20. Management cited solid first-half performance and mitigation of NHP supply constraints, partly offset by near-term demand trends as biopharmaceutical clients reprioritize pipelines and tighten R&D budgets. Segment results were mixed: DSA revenue rose 12.1% to $663.5 million with a GAAP operating margin of 24.3%, while Manufacturing Solutions revenue fell 4.2% to $186.5 million and its GAAP operating margin dropped to 13.1% from 32.1%. The filing also notes that interest expense rose to $35.0 million in the quarter from $3.7 million a year earlier, and that the company is hosting a virtual Meeting with Management on September 21, 2023. Forward-looking statements, including risks tied to NHP supply and U.S. Department of Justice investigations into the Cambodia NHP supply chain, are described in the company's Form 10-K filed February 22, 2023.
Charles River Laboratories International 8-K Report, Shareholder Vote Results (May 15, 2023)
Charles River Laboratories International, Inc. filed this Item 5.07 report to disclose the results of its Annual Meeting of Shareholders, held on May 9, 2023. Shareholders elected all eleven director nominees to serve until the 2024 Annual Meeting. Martin W. Mackay drew the most opposition, with 28,520,093 votes for and 17,471,571 against, and Deborah T. Kochevar also received 6,572,677 votes against. The filing refers to a proxy statement dated March 30, 2023 for further detail on the proposals. Shareholders approved, on an advisory basis, the compensation of the named executive officers, with 40,252,161 votes for and 5,727,678 against. On the frequency of future say-on-pay votes, a majority favored an annual vote: 45,471,178 shares voted for one year, compared with 10,778 for two years and 515,767 for three years. The board said it currently intends to hold the advisory compensation vote every year until the next required frequency vote. Shareholders also ratified PricewaterhouseCoopers LLP as independent auditors for fiscal 2023, with 45,515,845 votes for and 2,419,202 against. Shareholders did not approve a shareholder proposal submitted by PETA asking the company to publish a report on non-human primates it imports. The proposal received 16,382,651 votes for and 29,395,105 against, with 233,421 abstentions and 1,946,418 broker non-votes. Computershare Trust Company, N.A., the company's transfer agent, served as independent proxy tabulator and Inspector of Election.
Charles River Laboratories International Quarterly Report for Q2 Ended Apr 1, 2023
Charles River Laboratories International, Inc. reported revenue of $1,029.4 million for the three months ended April 1, 2023, up 12.6% from $913.9 million a year earlier, driven mainly by increased demand and pricing in its Safety Assessment business and the Explora BioLabs acquisition, partially offset by the Avian divestiture and currency effects. Operating income rose to $167.9 million from $148.8 million, with the operating margin flat at 16.3%. Net income attributable to common shareholders was $103.1 million, or $2.01 per diluted share, compared with $93.0 million, or $1.81 per diluted share, a year earlier. Interest expense more than doubled to $34.4 million from $9.4 million, reflecting higher interest rates, and the effective tax rate rose to 20.7% from 14.1%. Segment results were uneven. DSA revenue grew 21.7% to $662.4 million with operating income up 63.3%, while Manufacturing operating income fell to $2.1 million from $46.4 million on higher costs in Biologics Solutions and the Avian divestiture. RMS operating income declined 15.6% to $40.4 million, mainly due to timing of large research model sales in China and costs tied to Explora BioLabs. Cash provided by operations was $109.4 million, while capital expenditures were $106.9 million. The company made no share repurchases in the quarter and had $129.1 million remaining under its $1.3 billion authorization. Total debt and finance leases were $2.77 billion as of April 1, 2023. The filing also discloses that the U.S. Department of Justice and U.S. Fish and Wildlife Service are investigating the company's shipments of non-human primates from Cambodia, which has prompted a grand jury subpoena and a voluntary suspension of future shipments from that country. The company says it is cooperating and believes the concerns are without merit, but it cannot predict the timing, outcome, or possible impact, including potential fines, penalties or liabilities.